Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
| Title: | Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. |
|---|---|
| Authors: | Boothman AM; Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom. Electronic address: Anne-Marie.Boothman@astrazeneca.com.; Scott M; Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.; Ratcliffe M; Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.; Whiteley J; Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.; Dennis PA; Global Medicines Development, AstraZeneca, Gaithersburg, Maryland.; Wadsworth C; Global Medicines Development, AstraZeneca, Alderley Park, United Kingdom.; Sharpe A; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.; Rizvi NA; Division of Hematology and Oncology, Columbia University Medical Center, New York, New York.; Garassino MC; Thoracic Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Walker J; Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom. |
| Source: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Aug; Vol. 14 (8), pp. 1390-1399. Date of Electronic Publication: 2019 May 04. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2016- : New York, NY : Elsevier; Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins, c2006- |
| MeSH Terms: | Antibodies, Monoclonal/*therapeutic use ; Antineoplastic Agents, Immunological/*therapeutic use ; B7-H1 Antigen/*biosynthesis ; Carcinoma, Non-Small-Cell Lung/*drug therapy ; Carcinoma, Non-Small-Cell Lung/*immunology ; Lung Neoplasms/*drug therapy ; Lung Neoplasms/*immunology; B7-H1 Antigen/immunology ; Carcinoma, Non-Small-Cell Lung/pathology ; Lung Neoplasms/pathology ; Aged ; Clinical Trials, Phase II as Topic ; Female ; Humans ; Immunohistochemistry ; Male ; Middle Aged |
| Abstract: | Introduction: We evaluated the impact of patient characteristics, sample types, and prior non-immunotherapy treatment on tumor cell (TC) programmed cell death ligand 1 (PD-L1) expression using samples from patients with advanced NSCLC.; Methods: Patients (N = 1590) screened for the ATLANTIC study submitted a recently acquired (≤3 months) or archival (>3 months to >3 years old) tumor sample for PD-L1 assessment using the VENTANA PD-L1 (SP263) Assay with a cutoff of ≥25% of TCs expressing PD-L1 (TC ≥25%). Samples were acquired either before or after the two or more treatment regimens required for study entry and sample age varied among patients. A subset of patients (n = 123) provided both recent and archival samples.; Results: A total of 517 of 1590 (32.5%) patients had TC greater than or equal to 25%: prevalence was greater in smokers versus nonsmokers (p = 0.0005) and those with EGFR- versus EGFR+ tumors (p = 0.0002); these effects were independent. Prevalence of TC greater than or equal to 25% was increased in recent metastatic versus primary (p = 0.005) and recent versus archival (p = 0.039) samples. Chemotherapy or radiotherapy, but not tyrosine kinase inhibition, before sampling was associated with significantly increased PD-L1 prevalence. PD-L1 status (TC ≥25% cutoff) remained unchanged in 74.0% of patients with recent and archival samples; where PD-L1 status changed, it was more likely to increase than decrease over time or with intervening treatment.; Conclusions: Several factors potentially impact PD-L1 TC greater than or equal to 25% prevalence in advanced NSCLC; however, no characteristic can be considered a surrogate for PD-L1 expression. Fresh biopsy may provide more accurate assessment of current tumoral PD-L1 expression where a low/negative result is seen in an archival sample, especially if the patient has received intervening therapy.; (Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.) |
| Comments: | Comment in: J Thorac Oncol. 2019 Sep;14(9):e211. doi: 10.1016/j.jtho.2019.05.034.. (PMID: 31445743); Comment in: J Thorac Oncol. 2019 Sep;14(9):e212-e213. doi: 10.1016/j.jtho.2019.06.022.. (PMID: 31445744) |
| Contributed Indexing: | Keywords: Diagnostic test; Immunohistochemistry; Immunotherapy; NSCLC; Programmed cell death ligand 1 |
| Substance Nomenclature: | 0 (Antibodies, Monoclonal); 0 (Antineoplastic Agents, Immunological); 0 (B7-H1 Antigen); 0 (CD274 protein, human); 28X28X9OKV (durvalumab) |
| Entry Date(s): | Date Created: 20190508 Date Completed: 20200723 Latest Revision: 20200723 |
| Update Code: | 20260130 |
| DOI: | 10.1016/j.jtho.2019.04.025 |
| PMID: | 31063864 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't